GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » EPS without NRI

Mega Genomics (HKSE:06667) EPS without NRI : HK$0.13 (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics EPS without NRI?

Mega Genomics's earnings per share without non-recurring items for the six months ended in Jun. 2024 was HK$0.17. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.13.

During the past 12 months, Mega Genomics's average earnings per share (NRI) Growth Rate was 436.00% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -40.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Mega Genomics's EPS without NRI or its related term are showing as below:

HKSE:06667' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -73.5   Med: -57.1   Max: -40.7
Current: -40.7

During the past 5 years, Mega Genomics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -40.70% per year. The lowest was -73.50% per year. And the median was -57.10% per year.

HKSE:06667's 3-Year EPS without NRI Growth Rate is ranked worse than
92.22% of 167 companies
in the Medical Diagnostics & Research industry
Industry Median: 5.6 vs HKSE:06667: -40.70

Mega Genomics's EPS (Diluted) for the six months ended in Jun. 2024 was HK$0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.17.

Mega Genomics's EPS (Basic) for the six months ended in Jun. 2024 was HK$0.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.17.


Mega Genomics EPS without NRI Historical Data

The historical data trend for Mega Genomics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics EPS without NRI Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
0.16 0.39 0.79 - 0.08

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only 0.10 -0.10 0.12 -0.04 0.17

Competitive Comparison of Mega Genomics's EPS without NRI

For the Diagnostics & Research subindustry, Mega Genomics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Genomics's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Mega Genomics's PE Ratio without NRI falls into.


;
;

Mega Genomics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mega Genomics  (HKSE:06667) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mega Genomics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Mega Genomics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Genomics Business Description

Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Executives
Dongyin Industrial (shenzhen) Co., Ltd. 2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd. 2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership) 2106 Person having a security interest in shares
Yurong Technology Limited 2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd. 2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited 2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership) 2106 Person having a security interest in shares
Guo Meiling 2101 Beneficial owner
Yu Rong 2501 Other
Lin Lin 2101 Beneficial owner
Infinite Galaxy Health Limited 2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other

Mega Genomics Headlines

No Headlines